Global Remdesivir Market Forecast and Trends
The global market for Remdesivir is
expected to expand at an impressive pace during the forecast period due, among
others, to the growing use of the drug in the treatment of various diseases
such as COVID-19, Ebola, SARS-COV, MERS-COV. The use of the COVID-19 drug,
which once failed to treat Ebola, has now been granted an orphan drug status
and clinical trials have begun to determine its efficacy in the treatment of
novel coronavirus disease.
According to Gilead, the outcomes of the
global, placebo-controlled trial conducted by the National Institute for
Allergy and Infectious Diseases (NIAID) are promising, showing that patients
with Covid-19 receiving Remdesivir recovered faster than comparable patients
receiving placebo. Gilead Sciences, Inc. is currently conducting phase 3
clinical trials in Asia-Pacific, Europe and the US. Gilead published
preliminary findings from its clinical trial on its antiviral drug Remdesivir,
showing progress in at least 50% of COVID-19 patients treated with a 5-day dose
of the drug. A research was then published by the National Institute of Allergy
and Infectious Diseases that showed Covid-19 patients who took Remdesivir
typically recovered after 11 days, four days faster than those who did not take
Global Remdesivir Market: Overview
Remdesivir is a nucleotide analog particularly to
adenosine which shuts down the process of viral replication by inhibiting the
activity of an important viral enzyme RNA-dependent polymerase RNA. The drug
ultimately induces mutation in the viral genome and inhibits the functioning of
polymerase enzymes, which leads to premature termination of viral replication.
global demand for Remdesivir is driven by the growing prevalence of COVID-19
disease across all parts of the globe. It has not been clinically proven,
though, but the studies suggest that Remdesivir has been effective in treating
new patients with coronavirus disease across the globe. A research performed by
Gilead Sciences Inc. on 53 prospective COVID-19 patients showed signs of
progress in 36 patients, about 68% of the total number of patients. The Chinese
used the medication mostly for compassionate use. WHO has guided the start of
clinical trials for Remdesivir along with three other drugs found to be
effective in COVID-19 therapy. The drug has now reached phase 3 of clinical
trials and the world hopes it will emerge as a promising treatment for
coronavirus. Following these positive trials, the Food and Drug Administration
issued permission for the medication to treat Covid-19 for emergency use
authorization (EUA). That means the medication has not undergone the same
examination as therapies approved by the FDA, but it will allow doctors to
prescribe Remdesivir to patients hospitalized with the disease. All supply of
drugs will go to government for allocation across the nation.
Remdesivir is still in clinical trials
and was not FDA approved properly (approved in EUA category). This might hamper
growth in the business. In fact, the medication once failed to cure Ebola, and
there are many questions and misconceptions concerning its use on the market.
Additionally, the cost of this medication is not known and people expect it
would be very costly. This, too, could delay market growth by 2026. Countries
have also begun to focus on the generic versions of medications, which may have
a detrimental effect on consumer development.
Global Remdesivir Market: Route of
global market is bifurcated into oral and intravenous depending on the route of
administration. Amidst the segmentation the intravenous route of administration
is expected to dominate the market since the treatment of COVID-19 has been
given to all patients solely through this route.
Global Remdesivir Market: Application
market is segregated into Ebola, SARS-COV, MERS-COV, and COVID-19 based upon
application. The product COVID-19 is expected to dominate the market for its
successful use in the treatment of this disease. The drug has also entered
clinical trials in phase 3, and is expected to emerge as a promising treatment
choice for the pandemic. The drug also showed promising results for the
SARS-COV and MERS-COV animal models
Global Remdesivir Market: Regional Insights
Due to the presence of the major players operating on
the market, North America is projected to dominate the global Remdesivir market
during the forecast period. In addition, the drug manufacturer Gilead Sciences
is also headquartered in California, United States. At the other hand, the
Asia-Pacific market is also projected to see substantial growth due to the
widespread use of the medication for COVID-19 treatment in countries such as
China, Japan, among others. Europe is projected to witness substantial growth in
the overall demand for Remdesivir throughout the forecast period due to EMA's
recommendation for the use of Remdesivir in compassionate COVID-19 care.
Gilead Sciences, Inc., Bright Gene, Hainan Haiyao, Cipla, Pfizer, Merck,
Cayman Chemical, Kelun Pharma, Hunan Warrant Pharmaceutical, Dr. Reddy's
Laboratories and others are some of the major market leaders in Remdesivir.
Organic strategies such as product launches, mergers and collaborations are
used by the companies operating on the market to boost their share. Gilead
Sciences, Inc., for instance, has announced it will donate 1.5 million doses of
the medication for compassionate use. The company has also started
manufacturing liquid and freeze-dried ways to improve supplies.
Ø May, 2020: India
has obtained 1,000 doses of Remdesivir, approved by the U.S. Food and Drug
Administration for Covid-19 treatment, as part of the WHO's global solidarity
trials, but pharmaceutical companies in India will have to wait for the patent
route chosen by U.S. drug maker Gilead to start development here despite Indian
scientists synthesizing Key Starting Materials (KSMs) from Remdesivir.
Ø May 2020: The
World Health Organization is planning to involve United States government and
Gilead Sciences about how to make antiviral medication Remdesivir more widely
accessible for treating Covid-19 as evidence emerges on its efficacy. Gilead
expects to produce more than 140,000 rounds of its 10-day treatment scheme by
the end of May, and anticipates that by the end of this year it will deliver 1
million rounds. Gilead said next year it would be able to manufacture
"several million" rounds of their antiviral medication.
By Dosage Form
Ø Frozen Solution
Ø Lyophilized Solution
By Route of Administration
The objective of the Study:
To analyze and forecast the global Remdesivir
Market size of the market in terms of value.
To examine the careful market segmentation
and forecast the market size, in terms of value, based on the region by
The Global Remdesivir Market segmented into
five regions, namely, North America, Europe, Asia Pacific, Latin America,
Middle East & Africa and their leading countries.
To outline, categorized, and forecast the
global Remdesivir Market is based on the dosage, dosage form, route of
administration, distribution channel and application.
To examine competitive developments like technological
advancement and regulative framework within the global Remdesivir Market.
To highlight the impact analysis of the
factors affecting the market dynamics such as drivers, restraints,
opportunities, and challenges.
To strategically profile the key players and
comprehensively analyze their market shares along with detailing the
competitive landscape for market leaders.